



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/613,038

Confirmation No.: 9334

Applicant : Antonio J. GRILLO-LOPEZ et al.

Filed : July 10, 2000

Art Unit : 1644

Examiner : Ronald B. SCHWADRON

Docket No. : 22338-00602

Customer No. : 33694

MAIL STOP AMENDMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Listed on the accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97, and 1.98.

Applicants also direct the examiner's attention to the commonly owned, pending U.S. patent application listed below.

Serial No.	Filing Date	First Inventor
09/564,288	May 4, 2000	Curd
09/911,692	July 25, 2001	Anderson
09/911,703	July 25, 2001	Anderson
10/096,964	Mar. 14, 2002	Anderson
10/238,681	Sept. 11, 2002	Anderson
10/196,732	July 17, 2002	Grillo-López
10/850,712	May 21, 2004	Grillo-López
09/436,347	Nov. 9, 1999	White
09/628,187	July 28, 2000	White

Serial No.	Filing Date	First Inventor
09/762,587	Sept. 6, 2001	Grillo-López
10/440,186	May 19, 2003	Grillo-López

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This disclosure statement is filed before the mailing date of a final Office action under the provisions of 37 C.F.R. § 1.97(c)(2). As indicated on the fee transmittal that accompanies this submission, the Director is requested to charge the requisite fee (\$180), as well as any other fees that may be required to make this submission timely or proper, to our Deposit Account No. 18-1260.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO 1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

Respectfully submitted,



Jeffrey P. Kushan
Registration No. 48914
Attorney for Applicants

Date: 6/13/06

SIDLEY AUSTIN LLP
1501 K Street, N.W.
Washington, D.C. 20005
Phone: 202/736-8000
Fax: 202/736-8711

**INFORMATION
DISCLOSURE
STATEMENT**

Docket No. 22338-00602

Application No. 09/613,038

Applicant(s): Antonio J. Grillo-Lopez et al.

Examiner: Ronald B. Schwadron

Filing Date: July 10, 2000

Group Art Unit: 1644



U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	280	5,595,721	Jan. 21, 1997	Kaminsky			Sept. 16, 1993
	281	6,410,319	June 25, 2002	Raubitschek			Oct. 20, 1999
	282	20020041847	April 11, 2002	Goldenberg			Aug. 3, 2001
	283	20030133930	July 17, 2003	Goldenberg			Jan. 24, 2003
	284	20030219433	Nov. 27, 2003	Hansen			Feb. 14, 2003
	285	20040202658	Oct. 14, 2004	Benyunes			Apr. 6, 2004
	286	20050112130	May 26, 2005	Bhat			Nov. 5, 2004
	287	20050191300	Sept. 1, 2005	Goldenberg			Apr. 13, 2005
	288	20060024300	Feb. 2, 2006	Adams			July 26, 2005
	289	20060034835	Feb. 16, 2006	Adams			June 7, 2005
	290	20060051349	Mar. 9, 2006	Goldenberg			Sept. 12, 2005

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	291	WO 93/02108	Feb. 4, 1993	WIPO				
	292	WO 00/23573	Apr. 27, 2000	WIPO				
	293	WO 04/056312	July 8, 2004	WIPO				
	294	WO 04/091657	Oct. 28, 2004	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	295	J Elliott et al., "Semi-Specific Immuno-Absorption and monoclonal Antibody Therapy in ANCA Positive Vasculitis: Experience in Four Cases," <i>Autoimmunity</i> 28(3):163-71 (1998).
	296	M Kobayashi et al., "Immunohistochemical Analysis of Arterial Wall Cellular Infiltration in Buerger's Disease (Endoarteritis Obliterans)," <i>J. Vascular Surgery</i> 29(3):451-8 (March 1999).
	297	M Schoeffel et al., "Elevated Expression of HLA-Class II Antigen Positive Peripheral Blood T Lymphocytes in Multiple Sclerosis Results of an 18 Month Longitudinal Study," <i>Zeitschrift Fuer Klinische Medizin (Berlin)</i> 46(12):918-21 (1991).
	298	Y Goto et al., "Increased Production of B Cell Growth Factor (BCFG) in Sjorgen's Syndrome," <i>J. Autoimmunity</i> 9(4):545-50 (1996).
	299	M Falcone et al., "B Lymphocytes Are Crucial Antigen-Presenting Cells in the Pathogenic Autoimmune Response to GAD65 Antigen in Nonobese Diabetic Mice," <i>J. Immunol.</i> 161(3):1163-8 (Aug. 1, 1998)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	
SHEET 1 OF 2	



INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-00602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Ronald B. Schwadron
	Filing Date: July 10, 2000	Group Art Unit: 1644

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	300	L Chatenoud et al., "Anti-CD3 Antibody induces Long-Term Remission of Overt Autoimmunity in Nonobese Diabetic Mice," <i>Proc. Natl. Acad. Sci. (USA)</i> 91(1):123-7 (Jan. 4, 1994).
	301	Edwards, "Is Rheumatoid Factor Relevant?", <i>Challenges in Rheumatoid Arthritis</i> , Chapt. I, pp. 1-24 (HA Brid, ML Snaith eds. January 3, 1999).
	302	D Wendling et al., "A Randomized Double Blind, Placebo Controlled Multicenter Trial of Murine Anti-CD4 Monoclonal Antibody Therapy in Rheumatoid Arthritis," <i>J. Rheumatology</i> 25(8):1457-61 (Aug. 1998).
	303	EM Ruderman et al., "Oral glucocorticoids have no impact on the efficacy or safety profile of rituximab in rheumatoid arthritis (RA) patients with inadequate response to TNF inhibitors (REFLEX study)," forthcoming abstract publication.
	304	DG Maloney et al., "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma," <i>Blood</i> 84:2457-66 (1994).
	305	MJ Polyak & JP Deans, "Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure," <i>Blood</i> 99(9):3256-62 (2002).
	306	HB Lowman, "Differential Activities in a Series of Humanized Anti-CD20 Antibodies," presented at IBC Antibody Engineering Conference, San Diego, CA, December 2, 2003.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 2 OF 2